Index RUT
P/E -
EPS (ttm) -1.83
Insider Own 49.91%
Shs Outstand 113.97M
Perf Week 3.28%
Market Cap 88.37M
Forward P/E -
EPS next Y -0.30
Insider Trans -0.30%
Shs Float 57.13M
Perf Month 1.75%
Income -190.42M
PEG -
EPS next Q -0.16
Inst Own 43.01%
Short Float 11.20%
Perf Quarter 9.13%
Sales 0.00M
P/S -
EPS this Y 77.21%
Inst Trans 25.02%
Short Ratio 9.27
Perf Half Y -43.03%
Book/sh 1.28
P/B 0.61
EPS next Y 28.87%
ROA -81.40%
Short Interest 6.40M
Perf Year -77.99%
Cash/sh 1.61
P/C 0.48
EPS next 5Y -
ROE -102.85%
52W Range 0.62 - 6.12
Perf YTD 13.97%
Dividend Est. -
P/FCF -
EPS past 5Y -70.96%
ROI -117.23%
52W High -87.34%
Beta 0.78
Dividend TTM -
Quick Ratio 6.61
Sales past 5Y -37.09%
Gross Margin -
52W Low 24.35%
ATR (14) 0.04
Dividend Ex-Date -
Current Ratio 6.61
EPS Y/Y TTM 19.73%
Oper. Margin 0.00%
RSI (14) 53.13
Volatility 4.07% 5.92%
Employees 112
Debt/Eq 0.19
Sales Y/Y TTM -
Profit Margin -
Recom 4.25
Target Price 0.83
Option/Short Yes / Yes
LT Debt/Eq 0.11
EPS Q/Q -27.88%
Payout -
Rel Volume 0.06
Prev Close 0.80
Sales Surprise -
EPS Surprise 6.07%
Sales Q/Q -
Earnings Nov 02 BMO
Avg Volume 690.45K
Price 0.77
SMA20 1.70%
SMA50 4.29%
SMA200 -53.47%
Trades
Volume 4,751
Change -3.15%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-26-23 Downgrade
BofA Securities
Buy → Underperform
$17 → $1
Dec-22-23 Downgrade
Piper Sandler
Overweight → Neutral
Dec-22-23 Downgrade
Leerink Partners
Outperform → Market Perform
Dec-22-23 Downgrade
JP Morgan
Overweight → Underweight
Aug-18-23 Initiated
BofA Securities
Buy
$17
Oct-19-21 Resumed
Morgan Stanley
Overweight
$48
Aug-24-20 Initiated
SVB Leerink
Outperform
$41
Aug-24-20 Initiated
Morgan Stanley
Overweight
$49
Aug-24-20 Initiated
JP Morgan
Overweight
$50
Mar-18-24 03:53PM
Mar-13-24 11:53AM
10:00AM
Mar-12-24 05:50AM
Mar-06-24 06:17PM
05:37PM
Loading…
Mar-04-24 05:37PM
Feb-28-24 01:06AM
Feb-27-24 08:00AM
Feb-26-24 12:27PM
Feb-23-24 10:30AM
Jan-29-24 09:40AM
Jan-24-24 09:45AM
Jan-12-24 09:35AM
Jan-05-24 11:03AM
08:37AM
10:04AM
Loading…
Dec-26-23 10:04AM
Dec-22-23 09:31AM
08:30AM
07:10AM
07:00AM
Dec-05-23 08:55AM
Nov-16-23 07:00AM
Nov-02-23 10:04AM
07:00AM
Sep-21-23 02:44PM
Sep-14-23 09:59AM
Aug-28-23 07:00AM
Aug-03-23 07:00AM
Jul-21-23 07:17AM
Jul-12-23 03:12AM
07:34AM
Loading…
Jul-04-23 07:34AM
Jul-03-23 03:59AM
Jun-27-23 12:00PM
Jun-23-23 01:56PM
Jun-21-23 09:20PM
04:18PM
Jun-09-23 11:04AM
Jun-05-23 07:00AM
May-16-23 07:00AM
May-04-23 07:00AM
May-01-23 07:00AM
Apr-26-23 05:12PM
07:00AM
Mar-30-23 11:12AM
Feb-23-23 04:15PM
Feb-15-23 10:05AM
07:07AM
07:00AM
Feb-10-23 09:55AM
Feb-07-23 10:17AM
Feb-01-23 07:00AM
Jan-25-23 12:00PM
09:55AM
09:40AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-10-22 05:15PM
Nov-15-22 07:00AM
Nov-03-22 09:07AM
07:00AM
Oct-21-22 08:30AM
Sep-06-22 09:55AM
Aug-31-22 07:00AM
Aug-19-22 09:55AM
Aug-04-22 07:00AM
Aug-03-22 09:55AM
Aug-01-22 08:09AM
Jul-27-22 07:00AM
Jun-07-22 12:07PM
08:30AM
May-05-22 07:00AM
Apr-21-22 11:35AM
Apr-20-22 07:00AM
Apr-04-22 07:40PM
Mar-31-22 07:00AM
Mar-23-22 09:56AM
Mar-22-22 07:00AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Jan-05-22 07:30AM
Jan-03-22 04:05PM
Dec-16-21 04:05PM
Dec-11-21 01:00PM
Nov-17-21 11:57AM
Nov-15-21 07:00AM
Nov-10-21 11:48AM
Nov-05-21 07:00AM
Oct-29-21 09:47AM
Oct-06-21 11:31AM
Oct-05-21 06:48AM
Oct-04-21 07:00AM
Sep-29-21 02:09PM
07:00AM
Sep-07-21 07:00AM
Sep-03-21 08:19AM
Aug-26-21 01:41PM
Aug-06-21 07:00AM
Jun-27-21 03:19AM
May-06-21 07:00AM
Apr-07-21 09:45PM
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Sinha Vikas See Remarks Apr 22 '24 Sale 0.75 1,857 1,393 1,138,096 Apr 23 04:15 PM Miller Edward General Counsel Apr 22 '24 Sale 0.75 757 568 223,227 Apr 23 04:15 PM Hagen Brett R Chief Accounting Officer Apr 22 '24 Sale 0.75 480 360 77,619 Apr 23 04:15 PM Brainard Diana Chief Executive Officer Apr 19 '24 Sale 0.75 9,601 7,207 802,935 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 19 '24 Sale 0.75 1,521 1,142 1,139,953 Apr 23 04:15 PM Miller Edward General Counsel Apr 19 '24 Sale 0.75 626 470 223,984 Apr 23 04:15 PM Hagen Brett R Chief Accounting Officer Apr 19 '24 Sale 0.75 473 355 78,099 Apr 23 04:15 PM Brainard Diana Chief Executive Officer Apr 02 '24 Sale 0.77 1,533 1,183 812,536 Apr 04 04:15 PM Sinha Vikas See Remarks Apr 02 '24 Sale 0.77 885 683 1,141,474 Apr 04 04:15 PM Miller Edward General Counsel Apr 02 '24 Sale 0.77 368 284 224,610 Apr 04 04:15 PM Hagen Brett R Chief Accounting Officer Apr 02 '24 Sale 0.77 281 217 78,572 Apr 04 04:15 PM Brainard Diana Chief Executive Officer Feb 21 '24 Sale 0.71 5,155 3,650 814,069 Feb 22 04:18 PM Brainard Diana Chief Executive Officer Feb 20 '24 Sale 0.70 3,097 2,153 819,224 Feb 22 04:18 PM Sinha Vikas See Remarks Feb 20 '24 Sale 0.70 2,893 2,011 1,142,359 Feb 22 04:15 PM Hagen Brett R Chief Accounting Officer Feb 20 '24 Sale 0.70 494 343 78,853 Feb 22 04:15 PM Miller Edward General Counsel Feb 20 '24 Sale 0.70 385 268 224,978 Feb 22 04:16 PM Hagen Brett R Chief Accounting Officer Feb 08 '24 Sale 0.67 11,150 7,494 79,347 Feb 09 08:01 PM Brainard Diana Chief Executive Officer Feb 05 '24 Sale 0.67 41,421 27,752 822,321 Feb 06 04:38 PM Sinha Vikas See Remarks Feb 05 '24 Sale 0.67 18,331 12,282 1,145,252 Feb 06 04:46 PM Miller Edward General Counsel Feb 05 '24 Sale 0.67 8,869 5,942 225,363 Feb 06 04:40 PM Hagen Brett R Chief Accounting Officer Feb 05 '24 Sale 0.67 5,792 3,881 90,497 Feb 06 04:39 PM Brainard Diana Chief Executive Officer Jan 23 '24 Sale 0.67 9,500 6,369 863,742 Jan 25 04:15 PM Sinha Vikas See Remarks Jan 23 '24 Sale 0.67 3,205 2,150 1,163,583 Jan 25 04:15 PM Miller Edward General Counsel Jan 23 '24 Sale 0.67 1,302 873 234,232 Jan 25 04:15 PM Hagen Brett R Chief Accounting Officer Jan 23 '24 Sale 0.67 901 604 96,289 Jan 25 04:15 PM Brainard Diana Chief Executive Officer Jan 04 '24 Sale 0.64 1,664 1,063 873,242 Jan 08 04:15 PM Sinha Vikas See Remarks Jan 04 '24 Sale 0.64 961 614 1,166,788 Jan 08 04:15 PM Miller Edward General Counsel Jan 04 '24 Sale 0.64 424 271 235,534 Jan 08 04:15 PM Hagen Brett R Chief Accounting Officer Jan 04 '24 Sale 0.64 310 198 97,190 Jan 08 04:15 PM Hagen Brett R Chief Accounting Officer Dec 27 '23 Sale 0.74 28,335 20,838 97,500 Jan 02 07:36 PM Brainard Diana Chief Executive Officer Nov 20 '23 Sale 1.69 4,382 7,408 874,906 Nov 21 05:00 PM Brainard Diana Chief Executive Officer Nov 17 '23 Sale 1.63 2,689 4,386 879,288 Nov 21 05:00 PM Sinha Vikas See Remarks Nov 17 '23 Sale 1.63 2,490 4,061 1,167,749 Nov 21 05:00 PM Hagen Brett R Chief Accounting Officer Nov 17 '23 Sale 1.63 403 657 125,835 Nov 21 05:00 PM Sinha Vikas See Remarks Oct 20 '23 Sale 1.54 1,475 2,273 1,170,239 Oct 23 05:00 PM Hagen Brett R Chief Accounting Officer Oct 20 '23 Sale 1.54 357 550 126,238 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 19 '23 Sale 1.58 8,581 13,558 881,977 Oct 23 05:00 PM Sinha Vikas See Remarks Oct 19 '23 Sale 1.58 1,232 1,947 1,171,714 Oct 23 05:00 PM Hagen Brett R Chief Accounting Officer Oct 19 '23 Sale 1.58 358 566 126,595 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 03 '23 Sale 1.98 1,325 2,619 890,558 Oct 05 05:00 PM Sinha Vikas See Remarks Oct 03 '23 Sale 1.98 755 1,492 1,172,946 Oct 05 05:00 PM Hagen Brett R Chief Accounting Officer Oct 03 '23 Sale 1.98 222 439 126,953 Oct 05 05:00 PM Brainard Diana Chief Executive Officer Aug 18 '23 Sale 2.79 4,055 11,313 891,883 Aug 21 05:00 PM Brainard Diana Chief Executive Officer Aug 17 '23 Sale 2.50 11,361 28,351 895,938 Aug 21 05:00 PM Sinha Vikas See Remarks Aug 17 '23 Sale 2.50 10,516 26,243 1,173,701 Aug 21 05:00 PM Hagen Brett R Chief Accounting Officer Aug 17 '23 Sale 2.50 1,653 4,125 127,175 Aug 21 05:00 PM Sinha Vikas See Remarks Jul 20 '23 Sale 3.35 1,437 4,810 1,184,217 Jul 21 05:00 PM Hagen Brett R Chief Accounting Officer Jul 20 '23 Sale 3.35 342 1,145 128,828 Jul 21 05:00 PM Brainard Diana Chief Executive Officer Jul 19 '23 Sale 3.56 8,342 29,710 907,299 Jul 21 05:00 PM Sinha Vikas See Remarks Jul 19 '23 Sale 3.56 1,198 4,267 1,185,654 Jul 21 05:00 PM Hagen Brett R Chief Accounting Officer Jul 19 '23 Sale 3.56 342 1,218 129,170 Jul 21 05:00 PM Brainard Diana Chief Executive Officer Jul 05 '23 Sale 3.05 5,275 16,063 915,641 Jul 06 05:00 PM Sinha Vikas See Remarks Jul 05 '23 Sale 3.05 2,983 9,084 1,186,852 Jul 06 05:00 PM GILEAD SCIENCES, INC. 10% Owner Jun 27 '23 Buy 3.75 2,930,870 10,990,762 16,635,286 Jun 28 05:17 PM Hagen Brett R Chief Accounting Officer Jun 09 '23 Sale 5.64 5,045 28,453 129,512 Jun 13 05:00 PM Brainard Diana Chief Executive Officer May 18 '23 Sale 4.21 4,536 19,115 916,628 May 19 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite